Early cognitive impairment along with decreased BDNF in male and female patients with newly diagnosed multiple sclerosis

• Published in: Journal of neuroimmunology 2016
• Main Authors: Barbora, Prokopova, Miroslav, Vlcek, Adela, Penesova, Lucia, Grunnerova, Alexandra, Garafova, Natasa, Hlavacova, Peter, Turcani, Branislav, Kollar, Daniela, Jezova
• Format: Article
• Language: English
• Subjects: Allergy and Immunology; Neurology
• ISSN: 0165-5728
• DOI: 10.1016/j.jneuroim.2016.11.007

Abstract The aim of this study was to evaluate neuroendocrine activation during stress in patients with recently diagnosed multiple sclerosis before starting the immunomodulatory therapy (EDSS score ≤ 2.0). We verified the hypothesis that certain cognitive and affective dysfunction is present already at this early stage of the disease. The sample consisted of 38 subjects, which involved patients who were recently diagnosed multiple sclerosis and age- and sex-matched healthy volunteers. Stroop test served as mental stress model enabling measurement of cognitive performance. Present results showed increased state anxiety, depression scores and poorer performance in the Stroop test in the group of patients compared to healthy subjects. The cognitive dysfunction was particularly evident in male patients with simultaneously decreased concentrations of the brain-derived neurotrophic factor (BDNF) in plasma. The patients at this stage of the disease have not yet developed the hyperactivity of the hypothalamic-pituitary-adrenocortical axis. They showed normal levels of plasma copeptin and reduced aldosterone response to mental stress test in women only. Concentrations of plasma copeptin were higher in men compared to women. Very early stages of multiple sclerosis are accompanied by disturbances in psychological well-being, mild cognitive dysfunction and decreased plasma concentrations of BDNF, particularly in male patients.